YieldMax AI & Tech Portfolio Option Income ETF vs GSK plc — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $42.84 (market cap $135.69M), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 677.1× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and GSK plc pays a 3.9% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 61 Days and GSK plc for 93 Days on average.
| GPTY | GSK | |
|---|---|---|
Market Cap | $135.69M | $91.88B |
Volume | 97,442 | 7,730,529 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $61.18 |
52-Week Low | $34.73 | $43.24 |
Typical Hold Time | 61 Days | 93 Days |
Enterprise Value | — | $111.88B |
Dividend Yield | — | 3.9% |
Signals from Pluang's Aura AI — not financial advice
GPTY trades at $42.84, down 0.76% with a bullish technical outlook from moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.29-0.30, providing income generation. Recent coverage highlights the fund's AI-focused covered call strategy as offering high yield potential while retaining some upside participation in tech rallies.
The outlook remains positive for income-seeking investors, with the options-based strategy generating substantial distributions. Key risks include market volatility impacting the underlying AI portfolio and the trade-off between income generation and capital appreciation potential in strong bull markets.
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →